罗格列酮与阿尔茨海默病  

Rosiglitazone and Alzheimer's Disease

作　　者：张旭[1,2] 王蓉[1,2] 

机构地区：[1]首都医科大学宣武医院中心实验室北京市老年病医疗研究中心 [2]教育部神经变性病重点实验室

出　　处：《首都医科大学学报》2011年第1期95-99,共5页Journal of Capital Medical University

基　　金：国家"十一五"863计划"疫苗与抗体工程"资助项目(2006AA02A245);北京市自然科学基金(7082043);首都医学发展科研基金(2007-3108);北京市卫生系统高层次卫生技术人才计划资助项目(2009-3-64)~~

摘　　要：随着人类步入老龄化社会,阿尔茨海默病(Alzheimer's disease,AD)的发病率不断增加,但其发病机制仍不明确,缺乏有效的治疗手段。近年来研究发现AD的患病风险与2型糖尿病具有一定相关性。有证据表明,治疗2型糖尿病的噻唑烷二酮类氧化物酶体增殖物激活受体γ(peroxisome proliferator-activated receptor gamma,PPARγ)激动剂罗格列酮可以改善AD患者和AD动物模型中与此疾病相关的病理变化和学习记忆功能。本文对以上内容和罗格列酮对AD的作用机制进行综述。In modern aging society,the incidence of Alzheimer＇s disease（AD） has been increasing significantly.However,the pathogenesis of AD has not ever been elucidated,and effective treatment for AD is unavailable.Recent study reported that the risk for AD has a high correlation with Type Ⅱ diabetes.There is now an extensive evidence that has demonstrated the efficacy of peroxisome proliferator-activated receptor gamma（PPARγ） agonists rosiglitazone in ameliorating disease-related pathology and improved learning and memory in AD patients and animal models.These evidences and the mechanism of rosiglitazone are reviewed in this paper.

关 键 词：过氧化物酶体增殖物激活受体Γ 罗格列酮 阿尔茨海默病 Β-淀粉样肽 炎性反应 载脂蛋白E 

分 类 号：R741[医药卫生—神经病学与精神病学]